Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06806488

Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

This is a purely retrospective and observational monocentric study

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Marginal Zone B Cell Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, B-Cell, Marginal Zone Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

the study aimed at describing the characteristics and outcome of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018.
  • Age ≥ 18 years at enrolment.
  • Written informed consent (if applicable)

Exclusion criteria

  • none

Treatment and study plan

Primary outcomes

  1. clinical characteristics of Marginal zone lymphoma patients

    Time frame: through study completion, an average of 1 years

    to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.

Secondary outcomes

  1. effectiveness

    Time frame: through study completion, an average of 1 years

    It includes:

    • Description of treatment duration and causes of treatment discontinuation.
    • Description of adverse events / safety of the treatments
    • Assessment of patients' survival.
    • Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions.
    • Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases

  2. safety

    Time frame: through study completion, an average of 1 years

    It includes:

    • Description of treatment duration and causes of treatment discontinuation.
    • Description of adverse events / safety of the treatments
    • Assessment of patients' survival.
    • Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions.
    • Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases

Study contacts

Contact information is provided by the study sponsor or research team.

Alessandro Broccoli, MD

CONTACT

[email protected]

+39 0512143680

Pier Luigi Zinzani, MD

CONTACT

[email protected]

+39 0512143680

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Official study title

Retrospective Observational Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Acronym: MarZoLyOss

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 4, 2025
Registry last updated
Feb 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.